Phase II study of FOLFIRI + cetuximab as induction chemotherapy followed by FOLFIRI + bevacizumab based on early tumor shrinkage in chemotherapy-naive patients with RAS wild-type colorectal cancer - Phase II study of FOLFIRI + cetuximab as induction chemotherapy followed by FOLFIRI + bevacizumab based on early tumor shrinkage in chemotherapy-naive patients with RAS wild-type colorectal cancer

Department of Clinical Oncology, St. Marianna University School of Medicine0 个研究点目标入组 54 人开始时间: 2016年8月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Previous treatment with irinotecan, bevacizumab, cetuximab/panitumumab 2) Symptomatic brain metastasis 3) Intestinal paralysis/obstruction 4) Massive pleural effusion, ascites, or pericardial effusion 5) Uncontrolled diarrhea 6) Active synchronous or metachronous malignancy 7) Severe infectious disease 8) Grade2 or higher skin toxicity 9) Interstitial pneumonia or pulmonary fibrosis 10) Serious complication(uncontrolled diabetes, severe cardiac disease, renal failure, liver failure) 11) History of thromboembolism 12) Unhealed wounds 13) Previous treatment with radiotherapy for primary disease 14) Administration of aspirin 15) Carcinomatous meningitis, uncontrolled epilepsy, mental disorder 16) Systemic administration of steroid 17) History of severe allergy 18) Positive for HBs antigen 19) Women who are pregnant or patients who are unwilling to avoid pregnancy 20) Patients who are inappropriate for the study in the opinion of the investigator

发起方

Department of Clinical Oncology, St. Marianna University School of Medicine